1-furan-2-ylmethyl-6,7-dimethoxy-4-phenyl-phthalazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-furan-2-ylmethyl-6,7-dimethoxy-4-phenyl-phthalazine
• 英文别名: 1-(Furan-2-ylmethyl)-6,7-dimethoxy-4-phenylphthalazine
• 化学式: C₂₁H₁₈N₂O₃
• 分子量: 346.386
• InChiKey: XCHHXRZDRGBXMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  57.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-chloro-4-furan-2-ylmethyl-6,7-dimethoxy-phthalazine 、 苯基锂 在 palladium diacetate zinc(II) chloride 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醚 、 环己烷 为溶剂， 反应 2.0h， 以61%的产率得到1-furan-2-ylmethyl-6,7-dimethoxy-4-phenyl-phthalazine
  参考文献：
  名称：

  Phthalazine derivatives as phosphodiesterase 4 inhibitors

  摘要：

  本发明提供了一种从以下组中选择的化合物：N-3-乙酰基-1-(3,5-二氯吡啶-4-基甲基)-5-环戊氧基-6-甲氧基-4H-邻苯二嗪；6,7-二甲氧基-1-吡啶-4-基甲基-4-噻唑-2-基-邻苯二嗪；1-(6,7-二甲氧基-4-吡啶-4-基甲基-1H-邻苯二嗪-2-基)乙酮；2-甲磺酰基-6,7-二甲氧基-4-吡啶-4-基甲基-1,2-二氢邻苯二嗪；2-甲酰基-6,7-二甲氧基-4-吡啶-4-基甲基-1,2-二氢邻苯二嗪；1-(6,7-二甲氧基-4-吡啶-4-基甲基-1H-邻苯二嗪-2-基)-1-咪唑-1-基甲酮；1-(3,5-二氯吡啶-4-基甲基)-3-甲磺酰基-6-二氟甲氧基-5-(四氢呋喃-2-氧基)-4H-邻苯二嗪；以及其N→O衍生物和其药学上可接受的盐。本发明还提供了一种药物组合物，其含有上述化合物的治疗有效量与药学上可接受的载体混合。

  公开号：

  US06340684B1

文献信息

• PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS
  申请人：ZAMBON GROUP S.p.A.

  公开号：EP1098886A1

  公开（公告）日：2001-05-16
• US6340684B1
  申请人：——

  公开号：US6340684B1

  公开（公告）日：2002-01-22
• US6498160B2
  申请人：——

  公开号：US6498160B2

  公开（公告）日：2002-12-24
• [EN] PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS<br/>[FR] DERIVES PHTALAZINE UTILISES EN TANT QU'INHIBITEURS DE PHOSPHODIESTERASES 4
  申请人：ZAMBON SPA

  公开号：WO2000005219A1

  公开（公告）日：2000-02-03

  Compounds of formula (I) wherein B is NH, methylene, a C2-6 alkylene chain optionally branched and/or unsaturated and/or interrupted by a C5-7 cycloalkyl residue; A is phenyl or heterocycle optionally substituted; R represents two hydrogen atoms or a C=O group when ----- is a single bond or, when ----- is a double bond, is hydrogen, optionally substituted aryl or heterocycle, (C1-8)-alkyl, (C2-8)-alkenyl or (C2-8)-alkynyl optionally substituted by aryl or heterocycle; aryloxy, heterocyclyloxy, aryl-C1-4-alkoxy, heterocyclyl-C1-4-alkoxy, amino substituted by 1 or 2 C1-4-alkyl group(s), aryl-amino, heterocyclyl-amino, aryl-C1-4-alkylamino, heterocyclyl-C1-4-alkylamino; R1 is a C1-6-alkyl, aryl, aryl-C1-10-alkyl, C4-7-cycloalkyl group optionally containing an oxygen atom and/or substituted; R2 is a C1-6-alkyl, polyfluoroC1-6-alkyl group; R3, when ----- is a single bond, is (a) hydrogen; (b) C1-6-alkyl optionally substituted by aryl, by heterocycle or by a COR5 group wherein R5 is hydroxy, C1-4-alkoxy or hydroxyamino; (c) -COR6 wherein R6 is hydrogen, aryl, aryl-C1-6-alkyl, amino optionally alkylated or monohydroxylated, hydroxy, C1-4-alkoxy, carboxy, C1-4-alkoxycarbonyl, formula (II) or C1-4-alkyl optionally substituted by heterocycle; (d) C1-4 alkyl-sulfonyl; the N→O derivatives of the compounds of formula (I) and the pharmaceutically acceptable salts thereof; are PDE 4 inhibitors.
• Phthalazine derivatives as phosphodiesterase 4 inhibitors
  申请人：Zambon Group S.p.A.

  公开号：US06340684B1

  公开（公告）日：2002-01-22

  The present invention provides a compound selected from the group including: N-3-acetyl-1-(3,5-dichloropyridin-4-ylmethyl)-5-cyclopentyloxy-6-methoxy-4H-phthalazine; 6,7-dimethoxy-1-pyridin-4-ylmethyl-4-thiazol-2-yl-phthalazine; 1-(6,7-dimethoxy-4-pyridin-4-ylmethyl-1H-phthalazin-2-yl)ethanone; 2-methanesulphonyl-6,7-dimethoxy-4-pyridin-4-ylmethyl-1,2-dihydrophthalazine; 2-formyl-6,7-dimethoxy-4-pyridin-4-ylmethyl-1,2-dihydrophthalazine; 1-(6,7-dimethoxy-4-pyridin-4-ylmethyl-1H-phthalazin-2-yl)-1-imidazol-1-ylmethanone; 1-(3,5-dichloro-pyridin-4-ylmethyl)-3-methansulphonyl-6-difluoromethoxy-5-(tetrahydro-furan-2-yloxy)-4H-phthalazine; N→O derivatives thereof; and pharmaceutically acceptable salts thereof. The invention also provides a pharmaceutical composition, which contains a therapeutically effective amount of the above compound in admixture with a pharmaceutically acceptable carrier.

  本发明提供了一种从以下组中选择的化合物：N-3-乙酰基-1-(3,5-二氯吡啶-4-基甲基)-5-环戊氧基-6-甲氧基-4H-邻苯二嗪；6,7-二甲氧基-1-吡啶-4-基甲基-4-噻唑-2-基-邻苯二嗪；1-(6,7-二甲氧基-4-吡啶-4-基甲基-1H-邻苯二嗪-2-基)乙酮；2-甲磺酰基-6,7-二甲氧基-4-吡啶-4-基甲基-1,2-二氢邻苯二嗪；2-甲酰基-6,7-二甲氧基-4-吡啶-4-基甲基-1,2-二氢邻苯二嗪；1-(6,7-二甲氧基-4-吡啶-4-基甲基-1H-邻苯二嗪-2-基)-1-咪唑-1-基甲酮；1-(3,5-二氯吡啶-4-基甲基)-3-甲磺酰基-6-二氟甲氧基-5-(四氢呋喃-2-氧基)-4H-邻苯二嗪；以及其N→O衍生物和其药学上可接受的盐。本发明还提供了一种药物组合物，其含有上述化合物的治疗有效量与药学上可接受的载体混合。